Rusnano Teams With Domain Associates To Co-Fund Life Sciences Companies And Establish Pharma JV In Russia
This article was originally published in The Pink Sheet Daily
Executive Summary
Russian sovereign fund is co-investing with Domain in the VC’s portfolio life sciences companies, and the pair also will fund a manufacturing facility in Russia.
You may also be interested in...
Has Aldea Hit On A Sober Approach To Alcohol-Intoxication Therapy?
Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.
Financings Of The Fortnight: Rusnano Dodging Controversy, Transforming Into Private Equity Fund
The Russian sovereign fund is a major investor in several U.S. life sciences start-ups. Plus news on recent financings by SAGE Therapeutics, Macrogenics, G1 Therapeutics and TD1 Innovations.
Up Close With Russian Investor Rusnano: A Q&A With Anatoly Chubais
In 2007, the Russian government committed $10 billion to invest in nanotechnology. About half of that has been invested, with little to show for it so far. After a recent shake-up, Rusnano is looking to prove itself and attract the private investors that could allow it eventually to privatize.